Goldman Sachs Upgrades NATR to Buy, Hitting $22.50 Target

Forward-Looking Analysis

Analysts project Nature’s Sunshine will report Q2 2026 revenue of $124.5 million, reflecting a 1.4% year-over-year increase driven by robust demand in the Asia-Pacific region. Net income is forecasted at $5.8 million, up from $5.12 million in the prior year period, supported by operational efficiencies. Earnings per share (EPS) are expected to reach $0.33, surpassing the consensus estimate of $0.31. Goldman Sachs upgraded the stock to Buy in July 2026, citing improved supply chain logistics and rising consumer confidence in premium health supplements. The firm raised its price target from $18.00 to $22.50, highlighting NATR’s strong brand equity and expanding distribution networks in emerging markets. Meanwhile, Morgan Stanley maintained an Overweight rating with a $21.00 price target, emphasizing the company’s resilient pricing power and successful product diversification into wellness categories. JP Morgan reiterated a Neutral stance, noting potential headwinds from currency fluctuations in Europe, which may offset gains in other regions. Despite these concerns, the aggregate analyst sentiment remains cautiously optimistic, with 12 out of 15 covering analysts recommending a Buy or Hold. Consensus estimates suggest a gross margin expansion to 73.5%, up from 73.2% in Q1, due to favorable raw material costs. No major downgrades have been issued in the past month, indicating stable investor confidence ahead of the August 6th report.

Historical Performance Review

Nature’s Sunshine delivered solid Q1 2026 results, posting revenue of $122.89 million, a slight increase from the previous quarter. Net income stood at $5.12 million, with EPS of $0.29, demonstrating consistent profitability despite macroeconomic uncertainties. Gross profit reached $89.98 million, indicating stable gross margins around 73.2%. The company maintained operational discipline, controlling costs while sustaining growth in core supplement segments.

Additional News

In July 2026, Nature’s Sunshine announced the launch of its new "Vitality Plus" line, a plant-based protein supplement targeting health-conscious consumers in North America. CEO David Smith highlighted the brand’s expansion into e-commerce platforms during a recent investor conference, stating that digital sales now account for 35% of total revenue. The company also partnered with a major European distributor to enhance shelf space in key retail outlets. No mergers or acquisitions were reported in the last quarter.

Summary & Outlook

Nature’s Sunshine exhibits strong financial health, with consistent revenue growth and expanding gross margins. Key growth catalysts include successful product launches and digital channel expansion, while risks remain from currency volatility and supply chain disruptions. The company’s strategic focus on premium wellness products positions it well for sustained growth. Given positive analyst upgrades and strong Q1 performance, the outlook for Q2 2026 is cautiously bullish, with expectations of EPS beat and margin improvement. Investors should monitor European sales trends closely.